Monte Rosa Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 9, 2024
GLUE$10.50-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
| Common stock | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts)(unaudited) | Shares | Amount | Additionalpaid-incapital | Accumulatedothercomprehensive loss | Accumulateddeficit | TotalStockholders’equity |
| Balance—January 1, 2023 | 49,323,531 | $5 | 503,696 | $(1,752) | $(230,536) | $271,413 |
| Restricted common stock vesting | 33,192 | — | — | — | — | — |
| Exercise of common stock options | 4,261 | — | 18 | — | — | 18 |
| Provision for pension benefit obligation | — | — | — | 14 | — | 14 |
| Stock-based compensation expense | — | — | 3,974 | — | — | 3,974 |
| Unrealized gain on available-for-sale securities | — | — | — | 345 | — | 345 |
| Net Loss | — | — | — | — | (32,038) | (32,038) |
| Balance—March 31, 2023 | 49,360,984 | $5 | 507,688 | $(1,393) | $(262,574) | $243,726 |
| Balance—January 1, 2024 | 50,140,233 | $5 | 547,857 | $(2,724) | $(365,888) | $179,250 |
| Restricted common stock vesting | 4,691 | — | — | — | — | — |
| Exercise of common stock options | 45,108 | — | 246 | — | — | 246 |
| Provision for pension benefit obligation | — | — | — | 35 | — | 35 |
| Stock-based compensation expense | — | — | 4,873 | — | — | 4,873 |
| Unrealized loss on available-for-sale securities | — | — | — | (4) | — | (4) |
| Issuance of common stock | 10,272 | — | 87 | — | — | 87 |
| Net Loss | — | — | — | — | (31,968) | (31,968) |
| Balance—March 31, 2024 | 50,200,304 | $5 | 553,063 | $(2,693) | $(397,856) | $152,519 |
See accompanying notes to the condensed consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.